This result provides the possibility that inhibiting EGFR tyrosine signaling can be another promising treatment modality of the future for hypercholesterolemia, type 2 diabetes mellitus, or fatty liver. The gene discussed is EGFR; the disease is type 2 diabetes mellitus.